Investigation of cancer drug resistance mechanisms by phosphoproteomics

Publication type:
Journal article
Metadata:
Autoren
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000598124100001&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1016/j.phrs.2020.105091
Externe Identifier
  • Clarivate Analytics Document Solution ID: PE1IE
  • PubMed Identifier: 32712320
ISSN
1043-6618
Zeitschrift
PHARMACOLOGICAL RESEARCH
Schlüsselwörter
  • Cancer
  • Chemotherapy
  • Drug resistance
  • Phosphorylation
  • Proteomics
Artikelnummer
ARTN 105091
Datum der Veröffentlichung
2020
Status
Published
Titel
Investigation of cancer drug resistance mechanisms by phosphoproteomics
Sub types
  • Review
Ausgabe der Zeitschrift
160

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
DOI
10.1016/j.phrs.2020.105091
ISSN
1043-6618
Zeitschrift
Pharmacological Research
Sprache
en
Artikelnummer
105091
Paginierung
105091 - 105091
Datum der Veröffentlichung
2020
Status
Published
Herausgeber
Elsevier BV
Herausgeber URL
http://dx.doi.org/10.1016/j.phrs.2020.105091
Datum der Datenerfassung
2020
Titel
Investigation of cancer drug resistance mechanisms by phosphoproteomics
Ausgabe der Zeitschrift
160

Data source: Crossref

Abstract
Cancer cell mutations can be identified by genomic and transcriptomic techniques. However, they are not sufficient to understand the full complexity of cancer heterogeneity. Analyses of proteins expressed in cancers and their modification profiles show how these mutations could be translated at the functional level. Protein phosphorylation is a major post-translational modification critical for regulating several cellular functions. The covalent addition of phosphate groups to serine, threonine, and tyrosine is catalyzed by protein kinases. Over the past years, kinases were strongly associated with cancer, thus inhibition of protein kinases emanated as novel cancer treatment. However, cancers frequently develop drug resistance. Therefore, a better understanding of drug effects on tumors is urgently needed. In this perspective, phosphoproteomics arose as advanced tool to monitor cancer therapies and to discover novel drugs. This review highlights the role of phosphoproteomics in predicting sensitivity or resistance of cancers towards tyrosine kinase inhibitors and cytotoxic drugs. It also shows the importance of phosphoproteomics in identifying biomarkers that could be applied in clinical diagnostics to predict responses to drugs.
Addresses
  • Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomolecular Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany.
Autoren
DOI
10.1016/j.phrs.2020.105091
eISSN
1096-1186
Externe Identifier
  • PubMed Identifier: 32712320
Open access
false
ISSN
1043-6618
Zeitschrift
Pharmacological research
Schlüsselwörter
  • Animals
  • Humans
  • Neoplasms
  • Neoplasm Proteins
  • Proteome
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Proteomics
  • Protein Processing, Post-Translational
  • Phosphorylation
  • Drug Resistance, Neoplasm
  • Biomarkers, Tumor
Sprache
eng
Medium
Print-Electronic
Online publication date
2020
Paginierung
105091
Datum der Veröffentlichung
2020
Status
Published
Datum der Datenerfassung
2020
Titel
Investigation of cancer drug resistance mechanisms by phosphoproteomics.
Sub types
  • Review
  • Journal Article
Ausgabe der Zeitschrift
160

Data source: Europe PubMed Central

Abstract
Cancer cell mutations can be identified by genomic and transcriptomic techniques. However, they are not sufficient to understand the full complexity of cancer heterogeneity. Analyses of proteins expressed in cancers and their modification profiles show how these mutations could be translated at the functional level. Protein phosphorylation is a major post-translational modification critical for regulating several cellular functions. The covalent addition of phosphate groups to serine, threonine, and tyrosine is catalyzed by protein kinases. Over the past years, kinases were strongly associated with cancer, thus inhibition of protein kinases emanated as novel cancer treatment. However, cancers frequently develop drug resistance. Therefore, a better understanding of drug effects on tumors is urgently needed. In this perspective, phosphoproteomics arose as advanced tool to monitor cancer therapies and to discover novel drugs. This review highlights the role of phosphoproteomics in predicting sensitivity or resistance of cancers towards tyrosine kinase inhibitors and cytotoxic drugs. It also shows the importance of phosphoproteomics in identifying biomarkers that could be applied in clinical diagnostics to predict responses to drugs.
Date of acceptance
2020
Autoren
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/32712320
DOI
10.1016/j.phrs.2020.105091
eISSN
1096-1186
Zeitschrift
Pharmacol Res
Schlüsselwörter
  • Cancer
  • Chemotherapy
  • Drug resistance
  • Phosphorylation
  • Proteomics
  • Animals
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Drug Resistance, Neoplasm
  • Humans
  • Neoplasm Proteins
  • Neoplasms
  • Phosphorylation
  • Protein Kinase Inhibitors
  • Protein Processing, Post-Translational
  • Proteome
  • Proteomics
Sprache
eng
Country
Netherlands
Paginierung
105091
PII
S1043-6618(20)31399-2
Datum der Veröffentlichung
2020
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2021
Titel
Investigation of cancer drug resistance mechanisms by phosphoproteomics.
Sub types
  • Journal Article
  • Review
Ausgabe der Zeitschrift
160

Data source: PubMed

Beziehungen:
Property of

Tools